Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia

Parkinsonism and Related Disorders

Volumn 16, Issue 5, 2010, Pages 316-323

  Truong, Daniel ^a   Brodsky, Matthew ^b   Lew, Mark ^c   Brashear, Allison ^d   Jankovic, Joseph ^e   Molho, Eric ^f   Orlova, Olga ^g   Timerbaeva, Sofia ^h  

^a Parkinson's and Movement Disorder Institute   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d WAKE FOREST UNIVERSITY HEALTH SCIENCES   (United States)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

^f ALBANY MEDICAL CENTER   (United States)

^g I M SECHENOV FIRST MOSCOW STATE MEDICAL UNIVERSITY   (Russian Federation)

^h RESEARCH CENTER OF NEUROLOGY   (Russian Federation)

Author keywords

Botulinum toxin type A; Cervical dystonia; Dysport; Randomized, controlled trial; Spasmodic torticollis

Indexed keywords

BOTULINUM TOXIN A; PLACEBO;

ARM DISEASE; ARTICLE; ASTHENIA; CERVICAL DYSTONIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPHAGIA; FATIGUE; FEMALE; FLU LIKE SYNDROME; FURUNCULOSIS; HEADACHE; HUMAN; INFLUENZA; INJECTION SITE PAIN; LIMB PAIN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MUSCLE WEAKNESS; NAUSEA; NECK PAIN; OPEN STUDY; PAIN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCORING SYSTEM; SHOULDER PAIN; SINGLE DRUG DOSE; TORONTO WESTERN SPASMODIC TORTICOLLIS RATING SCALE; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VISUAL ANALOG SCALE;

ADULT; AGED; BOTULINUM TOXIN TYPE A; DISABILITY EVALUATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG MONITORING; FEMALE; HUMANS; INJECTIONS, INTRAOCULAR; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NEUROMUSCULAR AGENTS; PAIN MEASUREMENT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX; TORTICOLLIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77952958535     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2010.03.002     Document Type: Article

References (17)

1. Van Zandijcke M. Cervical dystonia (spasmodic torticollis). Some aspects of the natural history. Acta Neurol Belg 1995, 95:210-215.
2. Jankovic J., Leder S., Warner D., Schwartz K. Cervical dystonia: clinical findings and associated movement disorders. Neurology 1991, 41:1088-1091.
3. Kutvonen O., Dastidar P., Nurmikko T. Pain in spasmodic torticollis. Pain 1997, 69:279-286.
4. Jankovic J., Tsui J., Bergeron C. Prevalence of cervical dystonia and spasmodic torticollis in the United States general population. Parkinsonism Relat Disord 2007, 13:411-416.
5. Rondot P., Marchand M.P., Dellatolas G. Spasmodic torticollis-review of 220 patients. Can J Neurol Sci 1991, 18:143-151.
6. Molho E.S., Agarwal N., Regan K., Higgins D.S., Factor S.A. Effect of cervical dystonia on employment: a retrospective analysis of the ability of treatment to restore premorbid employment status. Mov Disord 2009, 24:1384-1387.
7. Simpson D.M., Blitzer A., Brashear A., Comella C., Dubinsky R., Hallett M., et al. Assessment: botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008, 70:1699-1706.
8. Odergren T., Tollback A., Borg J. Electromyographic single motor unit potentials after repeated botulinum toxin treatments in cervical dystonia. Electroencephalogr Clin Neurophysiol 1994, 93:325-329.
9. Costa J., Espirito-Santo C., Borges A., Ferreira J.J., Coelho M., Moore P., et al. Botulinum toxin type A therapy for cervical dystonia. Cochrane Database Syst Rev 2005, CD003633.
10. Jankovic J., Brin M.F. Therapeutic uses of botulinum toxin. N Engl J Med 1991, 324:1186-1194.
11. Consky E.S., Lang A.E. Clinical assessments of patients with cervical dystonia. Therapy with botulinum toxin 1994, 211-237. M. Dekker, New York. J. Jankovic, M. Hallett (Eds.).
12. Poewe W., Deuschl G., Nebe A., Feifel E., Wissel J., Benecke R., et al. What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using Dysport. German Dystonia Study Group. J Neurol Neurosurg Psychiatry 1998, 64:13-17.
13. Wissel J., Kanovsky P., Ruzicka E., Bares M., Hortova H., Streitova H., et al. Efficacy and safety of a standardised 500 unit dose of Dysport (Clostridium botulinum toxin type A haemaglutinin complex) in a heterogeneous cervical dystonia population: results of a prospective, multicentre, randomised, double-blind, placebo-controlled, parallel group study. J Neurol 2001, 248:1073-1078.
14. Truong D., Duane D.D., Jankovic J., Singer C., Seeberger L.C., Comella C.L., et al. Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study. Mov Disord 2005, 20:783-791.
15. Ware JE. How to Score Version 2 of the SF-36 Health Survey. 2002.
16. Haussermann P., Marczoch S., Klinger C., Landgrebe M., Conrad B., Ceballos-Baumann A. Long-term follow-up of cervical dystonia patients treated with botulinum toxin A. Mov Disord 2004, 19:303-308.
17. Kessler K.R., Skutta M., Benecke R. Long-term treatment of cervical dystonia with botulinum toxin A: efficacy, safety, and antibody frequency. German Dystonia Study Group. J Neurol 1999, 246:265-274.